Self-sampling is appropriate for detection of Staphylococcus aureus: a validation study

<p>Abstract</p> <p>Background</p> <p>Studies frequently use nasal swabs to determine <it>Staphylococcus aureus</it> carriage. Self-sampling would be extremely useful in an outhospital research situation, but has not been studied in a healthy population. We studied the similarity of self-samples and investigator-samples in nares and pharynxes of healthy study subjects (hospital staff) in the Netherlands.</p> <p>Methods</p> <p>One hundred and five nursing personnel members were sampled 4 times in random order after viewing an instruction paper: 1) nasal self-sample, 2) pharyngeal self-sample, 3) nasal investigator-sample, and 4) pharyngeal investigator-sample.</p> <p>Results</p> <p>For nasal samples, agreement is 93% with a kappa coefficient of 0.85 (95% CI 0.74-0.96), indicating excellent agreement, for pharyngeal samples agreement is 83% and the kappa coefficient is 0.60 (95% CI 0.43-0.76), indicating good agreement. In both sampling sites self-samples even detected more <it>S. aureus</it> than investigator-samples.</p> <p>Conclusions</p> <p>This means that self-samples are appropriate for detection of <it>Staphylococcus aureus</it> and methicillin-resistant <it>Staphylococcus aureus</it>.</p

Waarom Burgers risico's accepteren en waarom bestuurders dat niet zien

Dit essay bestrijdt de mythe dat burgers sterk risicomijdend zijn. Deze mythe heeft in de gemeenschap van politici, bestuurders en ambtenaren nog steeds de status van waarheid. Dat lokt een tragische paradox uit: juist omdat de overheid veronderstelt dat burgers risicomijdend zijn, benadrukt ze steeds de veiligheid van haar plannen, waardoor het maatschappelijke verzet zich richt op die claims van veiligheid. Denk aan de CO2-opslag in Barendrecht of de vaccinatiecampagne tegen HPV, die leidden tot reacties waarin alleszins bescheiden risico’s werden uitvergroot om de legitimiteit van deze plannen te ondermijnen. Daarin ziet de overheid op haar beurt weer een bevestiging van de mythe, hetgeen dit tragische patroon verder versterkt. Toch is dit een verkeerde interpretatie van het maatschappelijke verzet. In essentie gaat het niet om de vaststelling van de precieze omvang van het risico, maar om de morele vraag waarom het acceptabel is om een risico aan bepaalde groepen op te leggen. Over deze morele vraag zwijgt de overheid. Haar morele pleidooi is impliciet: wij mogen u dit opleggen, omdat er eigenlijk nauwelijks sprake is van een risico. Geen wonder dat het verzet dan maar op een punt kan aangrijpen: de onderbouwing van de claim dat de risico’s bescheiden en beheersbaar zijn. Die onderbouwing kent per definitie tekortkomingen en dus zien de burgers al snel hun vermoeden bevestigd dat de overheid relevant risico’s ontkent. Deze tragische interactie mondt ook uit in wat we nu de risico-regel-reflex noemen: een disproportionele overheidsreactie op veiligheidsrisico’s en –incidenten. De overheid reageert zelf disproportioneel, maar toch ziet ze zich eigenlijk vooral als slachtoffer van dit probleem, niet als medeveroorzaker. Het zijn de anderen – de politiek, de media, maar uiteindelijk de burgers – die een disproportionele reactie zouden afdwingen. Waarom? Omdat burgers risicomijdend zijn, geen tolerantie meer zouden hebben voor pech. En daarmee zijn we weer terug bij de mythe

Predictive Value of Updating Framingham Risk Scores with Novel Risk Markers in the U.S. General Population

Background: According to population-based cohort studies CT coronary calcium score (CTCS), carotid intima-media thickness (cIMT), high-sensitivity C- reactive protein (CRP), and ankle-brachial index (ABI) are promising novel risk markers for improving cardiovascular risk assessment. Their impact in the U.S. general population is however uncertain. Our aim was to estimate the predictive value of four novel cardiovascular risk markers for the U.S. general population. Methods and Findings: Risk profiles, CRP and ABI data of 3,736 asymptomatic subjects aged 40 or older from the National Health and Nutrition Examination Survey (NHANES) 2003–2004 exam were used along with predicted CTCS and cIMT values. For each subject, we calculated 10-year cardiovascular risks with and without each risk marker. Event rates adjusted for competing risks were obtained by microsimulation. We assessed the impact of updated 10-year risk scores by reclassification and C-statistics. In the study population (mean age 56±11 years, 48% male), 70% (80%) were at low (<10%), 19% (14%) at intermediate (≥10–<20%), and 11% (6%) at high (≥20%) 10-year CVD (CHD) risk. Net reclassification improvement was highest after updating 10-year CVD risk with CTCS: 0.10 (95%CI 0.02–0.19). The C-statistic for 10-year CVD risk increased from 0.82 by 0.02 (95%CI 0.01–0.03) with CTCS. Reclassification occurred most often in those at intermediate risk: with CTCS, 36% (38%) moved to low and 22% (30%) to high CVD (CHD) risk. Improvements with other novel risk markers were limited. Conclusions: Only CTCS appeared to have significant incremental predictive value in the U.S. general population, especially in those at intermediate risk. In future research, cost-effectiveness analyses should be considered for evaluating novel cardiovascular risk assessment strategies

Predictive value of updating framingham risk scores with novel risk markers in the U.S. general population

Background: According to population-based cohort studies CT coronary calcium score (CTCS), carotid intima-media thickness (cIMT), high-sensitivity C- reactive protein (CRP), and ankle-brachial index (ABI) are promising novel risk markers for improving cardiovascular risk assessment. Their impact in the U.S. general population is however uncertain. Our aim was to estimate the predictive value of four novel cardiovascular risk markers for the U.S. general population. Methods and Findings: Risk profiles, CRP and ABI data of 3,736 asymptomatic subjects aged 40 or older from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 exam were used along with predicted CTCS and cIMT values. For each subject, we calculated 10-year cardiovascular risks with and without each risk marker. Event rates adjusted for competing risks were obtained by microsimulation. We assessed the impact of updated 10-year risk scores by reclassification and C-statistics. In the study population (mean age 56±11 years, 48% male), 70% (80%) were at low (<10%), 19% (14%) at intermediate (≥10-<20%), an

Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study

Objective: To evaluate differences in first manifestations of cardiovascular disease between men and women in a competing risks framework. Design: Prospective population based cohort study. Setting: People living in the community in Rotterdam, the Netherlands. Participants: 8419 participants (60.9% women) aged ≥55 and free from cardiovascular disease at baseline. Main outcome measures First diagnosis of coronary heart disease (myocardial infarction, revascularisation, and coronary death), cerebrovascular disease (stroke, transient ischaemic attack, and carotid revascularisation), heart failure, or other cardiovascular death; or death from non-cardiovascular causes. Data were used to calculate lifetime risks of cardiovascular disease and its first incident manifestations adjusted for competing non-cardiovascular death. Results: During follow-up of up to 20.1 years, 2888 participants developed cardiovascular disease (826 coronary heart disease, 1198 cerebrovascular disease, 762 heart failure, and 102 other cardiovascular death). At age 55, overall lifetime risks of cardiovascular disease were 67.1% (95% confidence interval 64.7% to 69.5%) for men and 66.4% (64.2% to 68.7%) for women. Lifetime risks of first incident manifestations of cardiovascular disease in men were 27.2% (24.1% to 30.3%) for coronary heart disease, 22.8% (20.4% to 25.1%) for cerebrovascular disease, 14.9% (13.3% to 16.6%) for heart failure, and 2.3% (1.6% to 2.9%) for other deaths from cardiovascular disease. For women the figures were 16.9% (13.5% to 20.4%), 29.8% (27.7% to 31.9%), 17.5% (15.9% to 19.2%), and 2.1% (1.6% to 2.7%), respectively. Differences in the number of events that developed over the lifespan in women compared with men (per 1000) were −7 for any cardiovascular disease, −102 for coronary heart disease, 70 for cerebrovascular disease, 26 for heart failure, and −1 for other cardiovascular death; all outcomes manifested at a higher age in women. Patterns were similar when analyses were restricted to hard atherosclerotic cardiovascular disease outcomes, but absolute risk differences between men and women were attenuated for both coronary heart disease and stroke. Conclusions: At age 55, though men and women have similar lifetime risks of cardiovascular disease, there are considerable differences in the first manifestation. Men are more likely to develop coronary heart disease as a first event, while women are more likely to have cerebrovascular disease or heart failure as their first event, although these manifestations appear most often at older ages

Performance of Framingham cardiovascular disease (CVD) predictions in the Rotterdam Study taking into account competing risks and disentangling CVD into coronary heart disease (CHD) and stroke

AbstractBackgroundTo evaluate the performance of Framingham predictions of cardiovascular disease (CVD) risk corrected for the competing risk of non-CVD death, in an independent European cohort of older individuals and subsequently extend the predictions by disentangling CVD into coronary heart disease (CHD) and stroke separately.MethodsWe used the Rotterdam Study data, a prospective cohort study of individuals aged 55years and older (N=6004), to validate the Framingham predictions of CVD, defined as first occurrence of myocardial infarction, coronary death or stroke during 15years of follow-up, corrected for the competing risk of non-CVD death. We subsequently estimated the risks of CHD and stroke separately, and used the sum as a predictor for the total CVD risk. Calibration plots and c-statistics were used to evaluate the performance of the models.ResultsPerformance of the Framingham predictions was good in the low- to intermediate risk (≤30%, 15-year CVD risk) (17.5% observed vs. 16.6% expected) but poorer in the higher risk (>30%) categories (36.3% observed vs. 44.1% expected). The c-statistic increased from 0.66 to 0.69 after refitting. Separately estimating CHD and stroke revealed considerable heterogeneity with regard to the contribution of CHD and stroke to total CVD risk.ConclusionsFramingham CVD risk predictions perform well in the low- to intermediate risk categories in the Rotterdam Study. Disentangling CVD into CHD and stroke separately provides additional information about the individual contribution of CHD and stroke to total individual CVD risk